Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

Jorge F Saucedo, Luis Garza, David C Wolford, Stephen L Cook, Kodangudi B Ramanathan, Zakaria Matin, Frank A McGrew, Mary V Jacoski, Lisa K Jennings

Journal: The American journal of cardiology 2004;93(10):1279-82

PMID: 15135704

Full Text on Elsevier Science View on PubMed

Abstract

We performed a comparative analysis of platelet aggregation inhibition achieved with the glycoprotein IIb/IIIa inhibitors eptifibatide and tirofiban HCl in patients who underwent percutaneous coronary intervention and used light transmission aggregometric assays with D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone as an anticoagulant and 20 micromol of adenosine diphosphate as an agonist. Taking into account the differences in clinical efficacy of these 2 drugs in large trials investigating percutaneous coronary intervention, we hypothesized that the variable clinical effects might be related to variability in the magnitude and consistency of platelet aggregation inhibition achieved with dosing regimens of these glycoprotein IIb/IIIa inhibitors.

Address: University of Arkansas for Medical Sciences and Central Arkansas Veterans Health Care System, Little Rock, AR, USA.

DOI: 10.1016/j.amjcard.2004.02.014

Link outs

Free resources

Medical:

https://medlineplus.gov/coronaryarterydisease.html

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0002...

MeSH Terms: Angioplasty, Balloon, Coronary, Arkansas, Coronary Artery Disease, Eptifibatide, Female, Humans, Infusions, Intravenous, Male, Mississippi, Peptides, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex, Tennessee, Tirofiban, Tyrosine, United States